Profile data is unavailable for this security.
About the company
Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.
- Revenue in USD (TTM)0.00
- Net income in USD-144.90m
- Incorporated--
- Employees7.00
- LocationPortage Biotech IncClarence Thomas Building, Road TownP.O. Box 4649TORTOLA VG1110Virgin Islands (British)VGB
- Phone+1 4 169291806
- Fax+1 4 169296612
- Websitehttps://portagebiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hoth Therapeutics Inc | 0.00 | -7.70m | 4.69m | 2.00 | -- | 0.5398 | -- | -- | -2.02 | -2.02 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -70.17 | -157.07 | -77.15 | -177.32 | -- | -- | -- | -- | -- | -50.67 | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
Eiger Biopharmaceuticals Inc | 15.77m | -74.96m | 4.89m | 25.00 | -- | -- | -- | 0.3098 | -50.80 | -50.80 | 10.69 | -9.77 | 0.1985 | 0.0064 | 9.19 | 630,920.00 | -94.31 | -60.25 | -186.10 | -76.51 | 99.91 | -- | -475.26 | -823.59 | 0.6809 | -22.03 | 1.54 | -- | 16.98 | -- | 22.54 | -- | 10.51 | -- |
Emmaus Life Sciences Inc | 28.46m | -4.74m | 4.90m | 55.00 | -- | -- | -- | 0.1723 | -0.0931 | -0.0931 | 0.3905 | -0.6773 | 0.6349 | 0.8184 | 9.36 | 517,454.50 | -10.58 | -- | -- | -- | 93.69 | -- | -16.66 | -- | 0.1249 | 0.1426 | -- | -- | -10.77 | -- | 33.37 | -- | -- | -- |
Portage Biotech Inc | 0.00 | -144.90m | 4.95m | 7.00 | -- | 0.1545 | -- | -- | -7.96 | -7.96 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -111.60 | -19.70 | -113.27 | -26.48 | -- | -- | -- | -- | -- | -- | 0.0087 | -- | -- | -- | -520.10 | -- | -- | -- |
Applied DNA Sciences Inc | 5.52m | -12.50m | 4.96m | 53.00 | -- | -- | -- | 0.8992 | -17.13 | -17.13 | 7.67 | -0.0558 | 0.3893 | 10.38 | 4.64 | 104,110.80 | -87.15 | -88.57 | -111.09 | -121.91 | 33.98 | 44.35 | -223.89 | -113.26 | 1.54 | -- | -- | -- | -26.43 | 27.92 | -18.73 | -- | 33.80 | -- |
Processa Pharmaceuticals Inc | 0.00 | -9.83m | 5.00m | 13.00 | -- | 0.5626 | -- | -- | -6.29 | -6.29 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -87.82 | -84.35 | -102.32 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0012 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 5.05m | 9.00 | -- | 0.2234 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
Halberd Corp | 281.24k | 25.34k | 5.09m | 3.00 | 3.45 | -- | 200.51 | 18.09 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
Galera Therapeutics Inc | 0.00 | -45.75m | 5.11m | 7.00 | -- | -- | -- | -- | -0.9971 | -0.9971 | 0.00 | -2.48 | 0.00 | -- | -- | 0.00 | -115.30 | -83.69 | -142.79 | -97.54 | -- | -- | -- | -- | -- | -6.49 | 9.23 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
Pineapple Inc | 157.59k | 376.69k | 5.12m | -- | 0.6283 | -- | 13.43 | 32.47 | 0.1114 | 0.1114 | 0.0028 | -0.0318 | 0.0388 | -- | -- | -- | 9.28 | -- | 53.43 | -- | -412.55 | -- | 239.03 | -- | 0.00 | -- | -- | -- | -- | -- | -611.10 | -- | -- | -- |
Sonnet Biotherapeutics Holdings Inc | 92.74k | -8.43m | 5.14m | 12.00 | -- | 1.68 | -- | 55.37 | -5.28 | -5.28 | 0.0315 | 0.9813 | 0.0097 | -- | 0.2248 | 7,728.33 | -87.68 | -- | -194.11 | -- | -- | -- | -9,086.22 | -- | -- | -138.21 | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
HST Global Inc | 0.00 | -141.11k | 5.14m | 1.00 | -- | -- | -- | -- | -0.0269 | -0.0269 | 0.00 | -0.1193 | 0.00 | -- | -- | -- | -29,397.92 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -24.24 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
Lipella Pharmaceuticals Inc | 477.45k | -4.74m | 5.17m | 5.00 | -- | 1.87 | -- | 10.83 | -0.7633 | -0.7633 | 0.0747 | 0.3638 | 0.1232 | -- | 6.25 | 95,490.00 | -122.37 | -- | -146.33 | -- | -- | -- | -993.39 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
Helix BioMedix, Inc. | 2.07m | -2.58m | 5.23m | 8.00 | -- | 3.35 | -- | 2.53 | -15.60 | -15.60 | 12.48 | 6.95 | 0.8047 | 1.87 | 4.55 | 258,238.80 | -100.64 | -146.31 | -120.73 | -173.57 | 68.96 | 30.80 | -125.06 | -527.12 | 1.69 | -14.57 | 0.00 | -- | 122.07 | 92.80 | 67.73 | -- | -29.08 | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Mar 2024 | 1.67m | 8.42% |
Bison Wealth LLCas of 31 Mar 2024 | 213.40k | 1.08% |
Peak6 Capital Management LLCas of 31 Mar 2024 | 55.26k | 0.28% |
Millennium Management LLCas of 31 Mar 2024 | 32.83k | 0.17% |
Renaissance Technologies LLCas of 31 Mar 2024 | 31.66k | 0.16% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 28.50k | 0.14% |
Citadel Securities LLCas of 31 Mar 2024 | 22.89k | 0.12% |
IEQ Capital LLCas of 31 Mar 2024 | 16.65k | 0.08% |
XTX Markets LLCas of 31 Mar 2024 | 15.96k | 0.08% |
Brown Brothers Harriman & Co. (Investment Management)as of 31 Mar 2024 | 14.00k | 0.07% |